ArticleOncoimmunology2020
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2023Pooled it
- Identification of tumor-associated antigens with multi-cancer therapeutic potential.Frontiers in immunology · 2026Article
- Personalized medicine in triple-negative breast cancer: combining neoantigen vaccination and genomic profiling in a patient undergoing neoadjuvant chemotherapy.Frontiers in oncology · 2025Article
- Identification of BRCA new prognostic targets and neoantigen candidates from fusion genes.Discover oncology · 2024Article
- Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).Oncology letters · 2024Review
- Breast cancer, viruses, and human leukocyte antigen (HLA).Scientific reports · 2024Article
- Public neoantigens in breast cancer immunotherapy (Review).International journal of molecular medicine · 2024Review
- Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.Journal for immunotherapy of cancer · 2024Article
- Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.Heliyon · 2024Article
- In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.Vaccine · 2023Article
- Tumor neoantigens: Novel strategies for application of cancer immunotherapy.Oncology research · 2023Review
- Immunogenetic Profiles and Associations of Breast, Cervical, Ovarian, and Uterine Cancers.Cancer informatics · 2023Article
- Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.Breast cancer research and treatment · 2023Article
- Neoantigens and their potential applications in tumor immunotherapy.Oncology letters · 2022Review
- Breast cancer vaccines for treatment and prevention.Breast cancer research and treatment · 2022Review
- Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction.Frontiers in oncology · 2022Article
- Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma.Oncogene · 2021Article
- Article
- The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ breast cancer · 2021Article
- Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors acquire numerous mutations during development and progression. When translated into proteins, these mutations give rise to neoantigens that can be recognized by T cells and generate antibodies, representing an exciting direction of cancer immunotherapy. While neoantigens have been reported in many cancer types, the profiling of neoantigens often focused on the class-I subtype that are presented to CD8 + T cells, and the relationship between neoantigen load and clinical outcomes was often inconsistent among cancer types. In this study, we described an informatics workflow, REAL-neo, for identification, quality control (QC), and prioritization of both class-I and class-II human leukocyte antigen (HLA) bound neoantigens that arise from somatic single nucleotide mutations (SNM), small insertions and deletions (INDEL), and gene fusions. We applied REAL-neo to 835 primary breast tumors in the Cancer Genome Atlas (TCGA) and performed comprehensive profiling and characterization of the detected neoantigens. We found recurrent HLA class-I and class-II restricted neoantigens across breast cancer cases, and uncovered associations between neoantigen load and clinical traits. Both class-I and class-II neoantigen loads from SNM and INDEL were found to predict overall survival independent of tumor mutational burden (TMB), breast cancer subtypes, tumor-infiltrating lymphocyte (TIL) levels, tumor stage, and age at diagnosis. Our study highlighted the importance of accurate and comprehensive neoantigen profiling and QC, and is the first to report the predictive value of neoantigen load for overall survival in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.